|

nab-paclitaxel + cisplatin Clinical Trials

2 actively recruiting trials

▲ +1 trial since August 2026

Also known as: Chemotherapy

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Sun Yat-sen University1
  • Shanghai Chest Hospital1

Indications

  • Cancer2
  • Unresectable Locally Advanced Esophageal Cancer1
  • Esophageal Squamous Cell Carcinoma1
  • Esophageal Squamous Cell Carcinoma (ESCC)1

Other2 trials

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
Phase 1/2
Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.